Replies to post #83682 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

That's true, too. It goes to show that they're really positioning it as an adjunct of some kind, at least in that study.

A very curious decision to not test monotherapy, as well, considering the aggressive size of the study (54 patients?)